Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Sandeep R. Das, Brendan M. Everett, Kim K. Birtcher, et al.
Journal of the American College of Cardiology (2020) Vol. 76, Iss. 9, pp. 1117-1145
Open Access | Times Cited: 347

Showing 1-25 of 347 citing articles:

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Seth S. Martin, Aaron W. Aday, Zaid Almarzooq, et al.
Circulation (2024) Vol. 149, Iss. 8
Open Access | Times Cited: 882
2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction
Thomas M. Maddox, James L. Januzzi, Larry A. Allen, et al.
Journal of the American College of Cardiology (2021) Vol. 77, Iss. 6, pp. 772-810
Open Access | Times Cited: 757
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Circulation (2023) Vol. 148, Iss. 9
Open Access | Times Cited: 557
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association
Joshua J. Joseph, Prakash Deedwania, Tushar Acharya, et al.
Circulation (2022) Vol. 145, Iss. 9
Open Access | Times Cited: 376
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. S158-S190
Open Access | Times Cited: 327
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 315
Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US
Lauren A. Eberly, Lin Yang, Nwamaka D. Eneanya, et al.
JAMA Network Open (2021) Vol. 4, Iss. 4, pp. e216139-e216139
Open Access | Times Cited: 255
2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction
M. Kittleson, Gurusher Panjrath, Kaushik Amancherla, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 18, pp. 1835-1878
Open Access | Times Cited: 232
Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association
Rodica Pop‐Busui, James L. Januzzi, Dennis Bruemmer, et al.
Diabetes Care (2022) Vol. 45, Iss. 7, pp. 1670-1690
Open Access | Times Cited: 228
GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
Nikolaus Marx, Mansoor Husain, Michael Lehrke, et al.
Circulation (2022) Vol. 146, Iss. 24, pp. 1882-1894
Open Access | Times Cited: 214
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 9, pp. 833-955
Open Access | Times Cited: 211
American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update
Susan L. Samson, Priyathama Vellanki, Lawrence Blonde, et al.
Endocrine Practice (2023) Vol. 29, Iss. 5, pp. 305-340
Open Access | Times Cited: 203
Pharmacological treatment of hyperglycemia in type 2 diabetes
Simeon I. Taylor, Zhinous Shahidzadeh Yazdi, Amber L. Beitelshees
Journal of Clinical Investigation (2021) Vol. 131, Iss. 2
Open Access | Times Cited: 179
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S179-S218
Open Access | Times Cited: 177
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022

Diabetes Care (2021) Vol. 45, Iss. Supplement_1, pp. S144-S174
Open Access | Times Cited: 165
Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US
Lauren A. Eberly, Lin Yang, Utibe R. Essien, et al.
JAMA Health Forum (2021) Vol. 2, Iss. 12, pp. e214182-e214182
Open Access | Times Cited: 140
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
Hang‐Long Li, Gregory Y.H. Lip, Qi Feng, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 136
Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis
Απόστολος Τσάπας, Thomas Karagiannis, Panagiota Kakotrichi, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 9, pp. 2116-2124
Closed Access | Times Cited: 127
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Hiroyuki Tsutsui, Tomomi Ide, Hiroshi Ito, et al.
Journal of Cardiac Failure (2021) Vol. 27, Iss. 12, pp. 1404-1444
Open Access | Times Cited: 115
Kidney and heart failure outcomes associated with SGLT2 inhibitor use
Annemarie B. van der Aart‐van der Beek, Rudolf A. de Boer, Hiddo J.L. Heerspink
Nature Reviews Nephrology (2022) Vol. 18, Iss. 5, pp. 294-306
Open Access | Times Cited: 114
Pharmacotherapy of type 2 diabetes: An update and future directions
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, et al.
Metabolism (2022) Vol. 137, pp. 155332-155332
Closed Access | Times Cited: 95
Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs
Dhruv Mahtta, David J. Ramsey, Michelle Lee, et al.
Diabetes Care (2022) Vol. 45, Iss. 2, pp. 372-380
Open Access | Times Cited: 88
National Trends in Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Glucagon‐like Peptide‐1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020
Rishav Adhikari, Kunal Jha, Zeina Dardari, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 9
Open Access | Times Cited: 88
Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction
Jacob A. Udell, W. Schuyler Jones, Mark C. Petrie, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 20, pp. 2058-2068
Open Access | Times Cited: 78
2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction
Thomas M. Maddox, James L. Januzzi, Larry A. Allen, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 15, pp. 1444-1488
Closed Access | Times Cited: 67
Page 1 - Next Page

Scroll to top